Suven Life gets 2 patents for neuro-degenerative drugs

Suven Life Sciences Ltd today announced receiving two product patents - one from India (272835) and one from South Africa (2014/09244) for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

These patents are valid through 2028 and 2032 respectively, Suven stated in a release today.

''The granted claims of the patents are from the mechanism of action and include the class of selective 5-HT6 compounds and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, major depressive disorder (MDD), Parkinson and Schizophrenia,'' Suven stated in a release.

With these new patents, Suven has a total of 18 granted patents from India and 23 granted patents from South Africa. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Suven said products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally'' says Venkat Jasti, CEO of Suven.

''Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the company has 10 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development, targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.